Abstract: The present invention provides a cosmetic composition for inhibiting or improving seborrhea and a pharmaceutical composition for preventing, improving or treating seborrhea, each composition comprising a specific peptide as an active ingredient. The peptide remarkably decreases the interaction between p53 and MDM2 and thus remarkably increases the interaction between p53 and RNA Polymerase II (POLII), thereby being able to induce expressions of the cytokines that cause apoptosis of sebocytes.

Abstract: Provided is a method for preventing, ameliorating, or treating degenerative diseases caused by cellular senescence, preferably osteoarthritis or atherosclerosis, comprising a specific peptide as an active ingredient, where the peptide remarkably inhibits the interaction of p53 and FOXO4 (Forkhead box protein O4), thereby inhibiting the expression of a cellular senescence regulator.

Abstract: Provided is a peptide fragment derived from secreted frizzled protein 5 (Sfrp5), i.e., a peptide fragment selected from the group consisting of the peptides as set forth in SEQ ID NOs: 1 to 9 and a cosmetic composition for skin-whitening and/or inhibiting skin pigmentation comprising the same as an active ingredient. The peptide fragment inhibits melanin formation in melanocytes, thereby having an inhibitory activity against skin pigmentation. Further provided is a reagent for researching or analyzing the inhibition of Wnt signaling pathways comprising the peptide fragment.

Abstract: Provided is a peptide fragment derived from secreted frizzled protein 5 (Sfrp5), i.e., a peptide fragment selected from the group consisting of the peptides as set forth in SEQ ID NOs: 1 to 9 and a cosmetic composition for skin-whitening and/or inhibiting skin pigmentation comprising the same as an active ingredient. The peptide fragment inhibits melanin formation in melanocytes, thereby having an inhibitory activity against skin pigmentation. Further provided is a reagent for researching or analyzing the inhibition of Wnt signaling pathways comprising the peptide fragment.

Abstract: Provided is a peptide fragment derived from secreted frizzled protein 5 (Sfrp5), i.e., a peptide fragment selected from the group consisting of the peptides as set forth in SEQ ID NOs: 1 to 9 and a cosmetic composition for skin-whitening and/or inhibiting skin pigmentation comprising the same as an active ingredient. The peptide fragment inhibits melanin formation in melanocytes, thereby having an inhibitory activity against skin pigmentation. Further provided is a reagent for researching or analyzing the inhibition of Wnt signaling pathways comprising the peptide fragment.

Abstract: Provided is a pharmaceutical or cosmetic composition comprising adiponectin-derived peptide fragments, i.e., the peptides of SEQ ID NOs: 1 to 6 as an active ingredient. The peptides facilitate skin regeneration and moisturization, inhibit skin wrinkle, and have inhibitory activities against allergy and inflammation as well as metastasis of cancer cells.

Abstract: Provided is a peptide fragment derived from secreted frizzled protein 5 (Sfrp5), i.e., a peptide fragment selected from the group consisting of the peptides as set forth in SEQ ID NOs: 1 to 9 and a cosmetic composition for skin-whitening and/or inhibiting skin pigmentation comprising the same as an active ingredient. The peptide fragment inhibits melanin formation in melanocytes, thereby having an inhibitory activity against skin pigmentation. Further provided is a reagent for researching or analyzing the inhibition of Wnt signaling pathways comprising the peptide fragment.

Abstract: Provided are small peptide fragments derived from microphthalmia-associated transcription factor (MITF) and a method for preventing or treating melanoma using the same as an active ingredient. Further provided is a method for skin-whitening and/or for inhibiting skin pigmentation, using the peptide fragments as an active ingredient.

Abstract: Provided is a pharmaceutical or cosmetic composition comprising adiponectin-derived peptide fragments, i.e., the peptides of SEQ ID NOs: 1 to 6 as an active ingredient. The peptides facilitate skin regeneration and moisturization, inhibit skin wrinkle, and have inhibitory activities against allergy and inflammation as well as metastasis of cancer cells.

Abstract: The present invention provides small peptide fragments derived from microphthalmia-associated transcription factor (MITF) and a pharmaceutical composition for preventing or treating melanoma comprising the same as an active ingredient. And also, the present invention provides a cosmetic composition for skin-whitening and/or for inhibiting skin pigmentation, comprising the peptide fragments as an active ingredient.

Abstract: The present invention relates to a polypeptide derived from a highly conserved region (HCR) I-III of an extracellular region of a CD99 and CD99 family such as CD99L2 and PBDX(or XG), which are a kind of transmembrane protein, or a fused protein thereof. The polypeptide or the fused protein thereof has an activating function of inhibiting the extravasation of white blood cells, or inhibiting the growth and/or metastasis of cancer cells. The present invention also provides a polynucleotide coding the polypeptide, a vector including same, and a transformant transformed by the vector. In addition, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof for preventing or treating inflammatory diseases. Further, the present invention provides a is pharmaceutical composition including the polypeptide or the fused protein thereof inhibiting the growth and/or metastasis of cancer cells, i.e., a pharmaceutical composition for preventing or treating cancer.

Abstract: The present invention relates to a polypeptide derived from a highly conserved region (HCR) I-III of an extracellular region of a CD99 and CD99 family such as CD99L2 and PBDX (or XG), which are a kind of transmembrane protein, or a fused protein thereof. The polypeptide or the fused protein thereof has an activating function of inhibiting the extravasation of white blood cells, or inhibiting the growth and/or metastasis of cancer cells. The present invention also provides a polynucleotide coding the polypeptide, a vector including same, and a transformant transformed by the vector. In addition, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof for preventing or treating inflammatory diseases. Further, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof inhibiting the growth and/or metastasis of cancer cells, i.e., a pharmaceutical composition for preventing or treating cancer.

Abstract: Described is a polypeptide inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, a fusion protein thereof, a polynucleotide encoding the polypeptide, a vector including the polynucleotide, and a transformant transformed with the vector. Described is also a pharmaceutical composition for the prevention or treatment of inflammatory diseases, or the inhibition of the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof.